01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Electronic supplementary material
Background
Methods
Patients and specimens
Data collection
Immunohistochemistry and evaluation
Statistical analyses
Results
Expression of CCL17 and its correlation with clinicopathological characteristics
Characteristics
|
Patients
|
CCL17 expression
|
|||
---|---|---|---|---|---|
n
|
%
|
Low
|
High
|
P-value
|
|
All patients
|
286
|
100
|
143
|
143
|
|
Age, years
|
0.811
a
|
||||
mean ± SD
|
55.37 ± 13.24
|
55.69 ± 13.46
|
55.05 ± 13.06
|
||
Gender
|
0.368
b
|
||||
Female
|
87
|
30.4
|
47
|
40
|
|
Male
|
199
|
69.6
|
96
|
103
|
|
Tumor size, cm
|
0.173
a
|
||||
mean ± SD
|
4.81 ± 2.67
|
5.04 ± 2.76
|
4.58 ± 2.56
|
||
Pathological T stage
|
0.301
c
|
||||
pT1
|
181
|
63.3
|
85
|
96
|
|
pT2
|
26
|
9.1
|
16
|
10
|
|
pT3
|
75
|
26.2
|
40
|
35
|
|
pT4
|
4
|
1.4
|
2
|
2
|
|
Pathological N stage
|
1.000
b
|
||||
pNx
|
240
|
83.9
|
120
|
120
|
|
pN0
|
44
|
15.4
|
22
|
22
|
|
pN1
|
2
|
0.7
|
1
|
1
|
|
Distant metastasis
|
0.063
b
|
||||
No
|
271
|
94.8
|
132
|
139
|
|
Yes
|
15
|
5.2
|
11
|
4
|
|
TNM stage
|
0.122
c
|
||||
I
|
175
|
61.2
|
79
|
96
|
|
II
|
23
|
8.0
|
13
|
10
|
|
III
|
69
|
24.1
|
35
|
34
|
|
IV
|
19
|
6.6
|
14
|
5
|
|
Fuhrman grade
|
0.456
c
|
||||
1
|
32
|
11.2
|
17
|
15
|
|
2
|
209
|
73.1
|
99
|
110
|
|
3
|
41
|
14.3
|
25
|
16
|
|
4
|
4
|
1.4
|
2
|
2
|
|
Necrosis
|
0.866
b
|
||||
Absent
|
245
|
85.7
|
123
|
122
|
|
Present
|
41
|
14.3
|
20
|
21
|
|
ECOG PS
|
0.003
b
|
||||
0
|
208
|
72.7
|
93
|
115
|
|
≥ 1
|
78
|
27.3
|
50
|
28
|
|
UISS category
|
0.277
c
|
||||
Low risk
|
119
|
41.6
|
54
|
65
|
|
Mediate risk
|
127
|
44.4
|
63
|
64
|
|
High risk
|
40
|
14.0
|
24
|
16
|
|
SSIGN category
|
0.143
c
|
||||
0–3
|
218
|
76.2
|
105
|
113
|
|
5–7
|
62
|
21.8
|
33
|
29
|
|
8+
|
6
|
2.1
|
5
|
1
|
High CCL17 expression is associated with better prognosis
Variables
|
OS (
n = 286)
|
RFS (
n = 262)
|
||||
---|---|---|---|---|---|---|
HR (95%CI)
|
P-value†
|
p-value†
(bootstrap‡)
|
HR (95%CI)
|
P-value†
|
p-value†
(bootstrap‡)
|
|
Pathological T stage
|
<0.001
|
<0.001
|
||||
pT1
|
Reference
|
Reference
|
||||
pT2
|
2.655 (1.361–5.180)
|
0.004
|
0.005
|
2.586 (1.197–5.587)
|
0.016
|
0.011
|
pT3
|
2.879 (1.756–4.720)
|
<0.001
|
0.001
|
3.061 (1.795–5.221)
|
<0.001
|
0.002
|
pT4
|
3.809 (1.054–14.422)
|
0.027
|
0.292
|
8.842 (2.712–28.823)
|
<0.001
|
0.009
|
Distant metastasis
|
||||||
Yes
vs No
|
2.467 (1.283–4.744)
|
0.007
|
0.073
|
|||
Fuhrman grade
|
0.005
|
0.001
|
||||
1
|
Reference
|
Reference
|
||||
2
|
1.957 (0.701–5.466)
|
0.200
|
0.219
|
1.439 (0.563–3.674)
|
0.447
|
0.490
|
3
|
4.067 (1.353–12.223)
|
0.012
|
0.012
|
4.024 (1.433–11.301)
|
0.008
|
0.019
|
4
|
6.786 (1.494–30.828)
|
0.013
|
0.002
|
5.377 (1.258–22.981)
|
0.023
|
0.005
|
Necrosis
|
||||||
Present
vs Absent
|
2.180 (1.216–3.909)
|
0.009
|
0.063
|
2.191 (1.202–3.991)
|
0.010
|
0.018
|
ECOG PS
|
||||||
0
vs ≥1
|
2.123 (1.333–3.382)
|
0.002
|
0.004
|
2.356 (1.426–3.893)
|
0.001
|
0.002
|
CCL17 expression
|
||||||
High
vs Low
|
0.504 (0.309–0.824)
|
0.006
|
0.011
|
0.448 (0.267–0.751)
|
0.002
|
0.025
|
Extension of Prognostic Model with CCL17 expression for ccRCC
Models
|
Overall survival
|
Recurrence-free survival
|
||||
---|---|---|---|---|---|---|
C-index (95%CI)
|
Coefficient (95%CI)
|
P-value
|
C-index (95%CI)
|
Coefficient (95%CI)
|
P-value
|
|
CCL17
|
0.615 (0.563–0.667)
|
0.612 (0.555–0.670)
|
||||
TNM
|
0.706 (0.652–0.760)
|
0.658 (0.601–0.719)
|
||||
TNM + CCL17
|
0.751 (0.699–0.803)
|
0.045 (0.016–0.074)
|
0.003†
|
0.717 (0.657–0.776)
|
0.018 (0.022–0.093)
|
0.002†
|
SSIGN
|
0.632 (0.580–0.685)
|
0.674 (0.617–0.731)
|
||||
SSIGN + CCL17
|
0.679 (0.620–0.738)
|
0.017 (0.014–0.079)
|
0.006†
|
0.720 (0.661–0.778)
|
0.045 (0.019–0.071)
|
0.001†
|
UISS
|
0.735 (0.688–0.781)
|
0.710 (0.658–0.762)
|
||||
UISS + CCL17
|
0.771 (0.724–0.818)
|
0.036 (0.017–0.055)
|
<0.001†
|
0.752 (0.697–0.802)
|
0.047 (0.018–0.065)
|
0.001†
|
Nomogram
|
0.799 (0.754–0.844)
|
0.787 (0.735–0.840)
|
||||
Nomogram
vs SSIGN
|
0.167 (0.118–0.215)
|
<0.001‡
|
0.109 (0.064–0.155)
|
<0.001‡
|
||
Nomogram
vs UISS
|
0.064 (0.030–0.099)
|
<0.001‡
|
0.073 (0.031–0.115)
|
=0.001‡
|